Related Experiment Video
Updated: May 31, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors
Andreas Blum1, Jark Böttcher, Stefanie Dörr
1Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany.
Journal of Molecular Biology
|July 19, 2011
Summary
Drug design requires continuous structural analysis. Even with similar molecules, human immunodeficiency virus type 1 protease inhibitors showed distinct binding modes, highlighting the need for ongoing structural biology during lead optimization.
Area of Science:
- Biochemistry
- Structural Biology
- Medicinal Chemistry
Background:
- Structure-based drug design relies on consistent binding modes for lead optimization.
- X-ray crystallography typically reveals a single binding orientation for similar ligands.
- Iterative optimization cycles involve synthesis, biological evaluation, computational methods, and structural analysis.
Purpose of the Study:
- To investigate the binding modes of novel human immunodeficiency virus type 1 protease inhibitors.
- To understand how modifications in P1/P1' moieties affect inhibitor activity against specific mutations.
- To assess the consistency of binding orientations during lead optimization.
Main Methods:
- Cocrystallization of inhibitors with human immunodeficiency virus type 1 protease.
- X-ray crystallography to determine protein-ligand complex structures.
- Structural analysis of different crystal forms and binding modes.
Main Results:
- Modification of P1/P1' moieties altered inhibitor activity against the Ile84Val mutation.
- Cocrystallization yielded two different crystal forms with two distinct binding modes.
- The pyrrolidine nitrogen's interaction with catalytic aspartates was the only conserved feature.
- Binding modes differed significantly despite structural similarity of the ligands.
Conclusions:
- Observed binding modes can change during lead optimization, even for similar compounds.
- Structural biology must guide the entire lead optimization process.
- Relying on an initial binding orientation can lead to failed optimization efforts.
Related Concept Videos
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
00:49Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...